Insuman Rapid (Insulin Human)

Insulin Human, the active component of Insuman Rapid, binds to insulin receptors on muscle, fat and liver cells. This binding activates intracellular pathways that promote the movement of glucose‑transport proteins to the cell surface, increasing glucose uptake from the bloodstream and suppressing hepatic glucose production, thereby reducing blood sugar levels.

The dose of Insuman Rapid is individualized and set by a qualified prescriber based on factors such as the patient’s current blood‑glucose readings, carbohydrate intake, body weight, renal function, and overall treatment goals. Adjustments are made over time to maintain optimal glycemic control while minimizing the risk of hypoglycemia.

Insuman Rapid is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy and lactation when the benefits outweigh potential risks, but therapy should be guided by a healthcare professional familiar with the patient’s condition.

To order Insuman Rapid, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After receiving the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Insuman Rapid contains human insulin, whereas other rapid‑acting analogues such as insulin lispro, aspart or glulisine are modified molecules designed for faster absorption. All provide mealtime glucose control, but analogue insulins may have a slightly quicker onset and shorter duration. Choice of product depends on clinical response, patient preference, cost considerations and prescriber experience.

Insuman Rapid should be stored in a refrigerator at 2 °C to 8 °C (36 °F to 46 °F). Keep the vial in its original packaging, protect it from light, and avoid freezing. Once in use, the product may be kept at controlled room temperature for up to 28 days, but should not be shaken vigorously.

Insuman Rapid is administered by subcutaneous injection, typically into the abdomen, thigh, or upper arm. The injection should be given shortly before meals to cover the rise in blood glucose that follows eating. Proper technique includes rotating injection sites, using a sterile needle, and ensuring the dose is drawn accurately according to the prescriber’s instructions.

The most serious risks include severe hypoglycemia, which can cause loss of consciousness or seizures, and rare allergic reactions such as anaphylaxis. Patients should be educated to recognize early signs of low blood sugar, monitor glucose regularly, and seek immediate medical attention if they experience symptoms of a severe allergic response.

Insuman Rapid is contraindicated in individuals with a known hypersensitivity to human insulin or any of the product’s excipients. It should also be avoided in patients with severe hypoglycemia until the condition is corrected. Use in patients with uncontrolled adrenal or pituitary insufficiency requires caution and close medical supervision.